{"created":"2021-03-01T07:30:18.662422+00:00","id":50049,"links":{},"metadata":{"_buckets":{"deposit":"b272ac0a-80f4-4102-a5f2-affbf7be0d1f"},"_deposit":{"id":"50049","owners":[],"pid":{"revision_id":0,"type":"depid","value":"50049"},"status":"published"},"_oai":{"id":"oai:tsukuba.repo.nii.ac.jp:00050049","sets":["2780:1499","2780:2963","3:62:5298:7430"]},"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-02","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"126","bibliographicPageStart":"118","bibliographicVolumeNumber":"8","bibliographic_titles":[{"bibliographic_title":"CPT: Pharmacometrics & Systems Pharmacology"}]}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Plasma concentrations of dabigatran, an active principle of prodrug dabigatran etexilate (DABE), are increased by renal impairment (RI) or coadministration of a P‐glycoprotein inhibitor. Because the combined effects of drug–drug interactions and RI have not been evaluated by means of clinical studies, the decision of DABE dosing for RI patients receiving P‐glycoprotein inhibitors is empirical at its best. We conducted virtual drug–drug interactions studies between DABE and the P‐glycoprotein inhibitor verapamil in RI populations using physiologically based pharmacokinetic modeling. The developed physiologically based pharmacokinetic model for DABE and dabigatran was used to predict trough dabigatran concentrations in the presence and absence of verapamil in virtual RI populations. The population‐based physiologically based pharmacokinetic model provided the most appropriate dosing regimen of DABE for likely clinical scenarios, such as drug–drug interactions in this RI population based on available knowledge of the systems changes and in the absence of actual clinical studies.","subitem_description_type":"Abstract"}]},"item_5_publisher_27":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. "}]},"item_5_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"30659778","subitem_relation_type_select":"PMID"}}]},"item_5_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1002/psp4.12382","subitem_relation_type_select":"DOI"}}]},"item_5_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2019 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution- NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes."}]},"item_5_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"21638306","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"土岐, 浩介"},{"creatorName":"ドキ, コウスケ","creatorNameLang":"ja-Kana"},{"creatorName":"DOKI, Kosuke","creatorNameLang":"en"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"本間, 真人"},{"creatorName":"ホンマ, マサト","creatorNameLang":"ja-Kana"},{"creatorName":"HOMMA, Masato","creatorNameLang":"en"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Neuhoff, Sibylle","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Rostami-Hodjegan, Amin","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-05-20"}],"displaytype":"detail","filename":"CPT_8-2.pdf","filesize":[{"value":"419.7 kB"}],"format":"application/pdf","licensetype":"license_9","mimetype":"application/pdf","url":{"label":"CPT_8-2","url":"https://tsukuba.repo.nii.ac.jp/record/50049/files/CPT_8-2.pdf"},"version_id":"f0ddcf7d-6471-4c50-9cd8-46441e124b36"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling"}]},"item_type_id":"5","owner":"1","path":["2963","1499","7430"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-05-20"},"publish_date":"2019-05-20","publish_status":"0","recid":"50049","relation_version_is_last":true,"title":["Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling"],"weko_creator_id":"1","weko_shared_id":5},"updated":"2022-04-27T09:22:47.179674+00:00"}